Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Validation: the new challenge for pathology.

Robert D Cardiff1, Andrea Rosner, Michael A Hogarth

  • 1Center for Comparative Medicine, University of California, Davis, Davis, California 95616, USA. rdcardiff@ucdavis.edu

Toxicologic Pathology
|June 24, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

WISDOM randomized trial comparing risk-based versus annual breast cancer screening: study cohort characteristics and design.

NPJ breast cancer·2026
Same author

Autostaining Immune Multiplex Immunohistochemistry Panels and Imaging Analysis.

Methods in molecular biology (Clifton, N.J.)·2026
Same author

Targeting Wnt/β-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity.

The Journal of clinical investigation·2026
Same author

Breast cancer risk level and prediction of tumor aggressiveness in the Athena Breast Health Network.

Breast cancer research and treatment·2026
Same author

Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial.

JAMA·2025
Same author

Germline Pathogenic Variants Among Women Without a History of Breast Cancer: A Secondary Analysis of the WISDOM Randomized Clinical Trial.

JAMA internal medicine·2025
Same journal

Comparison of Standard Clinical Pathology Parameter Values in Fasted and Fed Rats and Non-human Primates.

Toxicologic pathology·2026
Same journal

Time-Dependent Autolysis in Ex Vivo-Maintained Rat Tissue in Saline: A Descriptive Study and Practical Guidance for Histopathologic Assessment.

Toxicologic pathology·2026
Same journal

New Approach Methodologies (NAMs) for Carcinogenicity Evaluation.

Toxicologic pathology·2026
Same journal

2025 International Academy of Toxicologic Pathology (IATP) Satellite Symposium: Pathology Working Groups (PWGs) in Toxicologic Pathology.

Toxicologic pathology·2026
Same journal

Toxicologic Pathology Forum*: Opportunities and Challenges in the Use of Artificial Intelligence in Nonclinical Toxicologic Histopathology Evaluations.

Toxicologic pathology·2026
Same journal

New Modalities and Carcinogenicity Assessment.

Toxicologic pathology·2026
See all related articles

Genetically Engineered Mice (GEM) models offer unique cancer phenotypes, advancing pathway pathology concepts. Improved computer-readable terminologies are essential for validating these mouse models against human diseases.

Area of Science:

  • Comparative Pathology
  • Translational Oncology
  • Bioinformatics

Background:

  • Validating mouse models of human cancer requires matching morphological attributes.
  • Current computer-readable vocabularies and diagnostic terminologies lack terms for new concepts like pathway pathology.

Purpose of the Study:

  • To address the need for improved terminologies in mouse pathology for model validation.
  • To explore the utility of Genetically Engineered Mice (GEM) in cancer research and validation.

Main Methods:

  • Analysis of histological phenotypes in GEM-induced tumors.
  • Comparison of GEM tumor phenotypes with traditional mouse models and human breast cancer.
  • Conceptualization of pathway pathology where tumor phenotype reflects genotype.

Related Experiment Videos

Main Results:

  • GEMs develop unique tumor phenotypes that can mimic human cancers, unlike traditional models.
  • GEM tumors exhibit distinct histological features, categorized into resemblance to MMTV-induced tumors, signature phenotypes, or mimicry of human cancers.
  • Phenotypes can be clustered based on shared structural and functional characteristics.

Conclusions:

  • Genetically Engineered Mice (GEM) provide superior models for human cancer research due to their unique, human-like tumor phenotypes.
  • The concept of pathway pathology, linking genotype to phenotype, is supported by GEM findings.
  • Revision and enhancement of current terminologies are crucial for effective computer-assisted validation of mouse cancer models.